Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Rectal Neoplasms 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Genital Neoplasms, Female 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1Appendiceal Neoplasms 1Anus Neoplasms 1

Interventions

Gemcitabine 5Cisplatin 5Oxaliplatin 4Magnetic Resonance Spectroscopy 4Leucovorin 4Fluorouracil 4durvalumab 3Taxes 3futibatinib 2fludarabine 2Specimen Handling 2Platinum 2Paclitaxel 2Nivolumab 2Irinotecan 2Folfox protocol 2Fluorodeoxyglucose F18 2Carboplatin 2Biopsy 21,2-diaminocyclohexaneplatinum II citrate 2zimberelimab 1ulixertinib 1tocilizumab 1tivozanib 1tislelizumab 1regorafenib 1pevonedistat 1pemigatinib 1pembrolizumab 1olutasidenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cholangiocarcinoma × Electrocardiography × 30 days × Clear all
NCT05185947 2026-05-29

Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
21 enrolled 21 charts
BreastGastrointestinalGynecologic

Appendiceal Neoplasms, Breast Neoplasms, Genital Neoplasms, Female, Ovarian Neoplasms, Peritoneal Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡